Galapagos NV (GLPG)

38.24 +0.28 (+0.74%) At close: 04:00PM EDT

Galapagos NV

Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
https://www.glpg.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,357

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Bart Filius MBA	Pres, COO, CFO & Member of Management Board	844.62k	N/A	1970
Mr. Michele Manto M.B.A.	Chief Commercial Officer & Member of Management Board	813.27k	N/A	N/A
Dr. Walid Abi-Saab M.D.	Exec. Officer	702.97k	N/A	1965
Dr. Paulus A. Stoffels M.D., Ph.D.	CEO, Chairman, Head of R&D & Member of Management Board	N/A	N/A	1962
Ms. Valeria Cnossen	Gen. Counsel & Member of Management Board	N/A	N/A	N/A
Ms. Annelies Missotten	Chief HR Officer & Member of Management Board	N/A	N/A	N/A
Ms. Sofie Van Gijsel	Head of Investor Relations	N/A	N/A	N/A
Marieke Vermeersch	Head of Corp. Communication	N/A	N/A	N/A
John Montana	Managing Director of Argenta	N/A	N/A	N/A
Ms. Chantal Tasset	Head of Devel.	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Corporate Governance

Galapagos NV’s ISS Governance QualityScore as of February 1, 2023 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.